Dena Burge, Leigh Hockett, Jordan Furlan, Anne Arundel County, Maryland, Cristine Ridey, and Patricia Sawczuk, individually and on behalf of all others similarly situated v. Teva Pharmaceuticals Industries, Ltd., Teva Pharmaceuticals USA, Inc., Teva Parenteral Medicines, Inc., Teva Neuroscience, Inc., Teva Sales & Marketing, Inc., Cephalon, Inc.

CourtDistrict Court, D. Kansas
DecidedJanuary 14, 2026
Docket2:22-cv-02501
StatusUnknown

This text of Dena Burge, Leigh Hockett, Jordan Furlan, Anne Arundel County, Maryland, Cristine Ridey, and Patricia Sawczuk, individually and on behalf of all others similarly situated v. Teva Pharmaceuticals Industries, Ltd., Teva Pharmaceuticals USA, Inc., Teva Parenteral Medicines, Inc., Teva Neuroscience, Inc., Teva Sales & Marketing, Inc., Cephalon, Inc. (Dena Burge, Leigh Hockett, Jordan Furlan, Anne Arundel County, Maryland, Cristine Ridey, and Patricia Sawczuk, individually and on behalf of all others similarly situated v. Teva Pharmaceuticals Industries, Ltd., Teva Pharmaceuticals USA, Inc., Teva Parenteral Medicines, Inc., Teva Neuroscience, Inc., Teva Sales & Marketing, Inc., Cephalon, Inc.) is published on Counsel Stack Legal Research, covering District Court, D. Kansas primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Dena Burge, Leigh Hockett, Jordan Furlan, Anne Arundel County, Maryland, Cristine Ridey, and Patricia Sawczuk, individually and on behalf of all others similarly situated v. Teva Pharmaceuticals Industries, Ltd., Teva Pharmaceuticals USA, Inc., Teva Parenteral Medicines, Inc., Teva Neuroscience, Inc., Teva Sales & Marketing, Inc., Cephalon, Inc., (D. Kan. 2026).

Opinion

IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF KANSAS

DENA BURGE, LEIGH HOCKETT, JORDAN FURLAN, ANNE ARUNDEL COUNTY, MARYLAND, CRISTINE Case No. 22-2501-DDC-TJJ RIDEY, and PATRICIA SAWCZUK, individually and on behalf of all others similarly situated,

Plaintiffs,

v.

TEVA PHARMACEUTICALS INDUSTRIES, LTD., TEVA PHARMACEUTICALS USA, INC., TEVA PARENTERAL MEDICINES, INC., TEVA NEUROSCIENCE, INC., TEVA SALES & MARKETING, INC., CEPHALON, INC.,

Defendants.

MEMORANDUM AND ORDER

United States Magistrate Judge Teresa J. James conducted an in camera review of documents that, according to plaintiffs, defendants improperly withheld as privileged. Judge James concluded that some of those documents aren’t privileged because the crime-fraud exception to attorney-client privilege applies. And so, she ordered defendants to produce the unredacted documents. Defendants have objected to Judge James’s Order (Doc. 248). Doc. 255. The court, as explained below, overrules their objection. I. Background The court assumes the reader’s familiarity with the underlying facts and procedural history of this litigation and thus recites only the immediately pertinent background. Plaintiffs took issue with defendants’ privilege log. Plaintiffs moved to compel production of some privilege-log entries under the crime-fraud exception to the attorney-client privilege. Doc. 177 at 7. Plaintiffs argued that defendants used attorneys “to facilitate statutory antitrust violations as well as to fraudulently conceal those violations, obscuring from the public and regulators that the two settlements were actually one settlement.” Id. Plaintiffs thus asked

Judge James to compel production or review the documents in camera. Id. at 10. Defendants opposed the motion to compel, arguing that alleged violations of the antitrust statutes don’t trigger the crime-fraud exception. Doc. 185 at 7. They also argued that plaintiffs had failed to allege all elements of fraudulent concealment, a failing fatal to their request for in camera review. Id. at 8. Judge James bought into one of plaintiffs’ theories, but not the other. She rejected plaintiffs’ theory that antitrust violations qualify as a crime or fraud and thus trigger the crime- fraud exception. Doc. 226 at 15–17. But Judge James also concluded that plaintiffs properly could use defendants’ alleged fraudulent concealment as a basis to apply the crime-fraud

exception. Id. at 17–18. She concluded that “fraudulent concealment and deceitful conduct by Defendants preventing Plaintiffs from asserting their claims in a timely fashion could constitute an eligible ‘fraud’ to invoke the crime-fraud exception to attorney-client privilege.” Id. at 18. Judge James also held that plaintiffs had shouldered their burden to demonstrate a prima facie case of fraudulent concealment. Id. at 21–22. Judge James then reviewed the disputed privilege log entries and sorted them into three categories: 1. “Emails regarding negotiation of the EpiPen patent litigation settlement with Mylan and Pfizer and the Nuvigil patent settlement with Mylan;” 2. “Emails regarding public statements concerning the EpiPen and/or Nuvigil patent litigation settlements; and”

3. “Emails regarding communication with the FTC concerning the settlements.”

Id. at 22. Judge James declined to review in camera the first category because those emails only addressed alleged antitrust violations, and Judge James had concluded that antitrust violations can’t trigger the crime-fraud exception. Id. at 22–23. But she agreed to review the other two categories in camera. Defendants haven’t objected to Judge James’s decision granting in camera review. Plaintiffs, for their part, asked Judge James to reconsider whether to include the first category of documents in the in camera review. Doc. 234 at 5–8. Plaintiffs argued that, under this court’s decision in In re Urethane Antitrust Litigation, the court needn’t separate the conspiracy from the fraudulent concealment of that conspiracy. Id. at 6 (citing In re Urethane Antitrust Litig., 913 F. Supp. 2d 1145, 1159 (D. Kan. 2012)). Put simply, “the Tenth Circuit has not required that the affirmative acts of concealment . . . be[] separate from the conspiracy.” In re Urethane, 913 F. Supp. 2d at 1159. And so, plaintiffs asserted, they want to show that defendants fraudulently concealed their scheme with both (a) announcements that hid the related nature of the settlements and (b) “acts promoting secrecy in the negotiations.” Doc. 234 at 7 (quotation cleaned up). So, plaintiffs asked Judge James to reconsider reviewing in camera, the emails about negotiation of the EpiPen patent litigation settlement and the Nuvigil patent litigation settlement. Judge James granted plaintiffs’ motion to reconsider, without ordering a response from defendants. Doc. 243. Judge James agreed that “emails regarding the negotiation of the alleged trade-for-delay scheme could be relevant to whether fraudulent concealment and deceitful conduct by Defendants prevented Plaintiffs from asserting their claims in a timely fashion so as to trigger the crime-fraud exception to attorney-client privilege[.]” Id. at 5–6 (quotation cleaned up). Defendants didn’t object to Judge James’s decision granting the motion to reconsider which, in effect, expanded the scope of the in camera review. Judges James then reviewed the documents in camera. She found “some but not all, of the redacted communications between Defendants and their attorneys to be probative of the

specific allegations of active and intentional fraudulent concealment by Defendants with the participation of their attorneys.” Doc. 248 at 7. And she thus ordered defendants to produce those communications, unredacted, to plaintiffs. Defendants have objected to this Judge James Order—Doc. 248—and that Order alone. Doc. 255 (“Defendants’ Objections to the Magistrate Judge’s In Camera Review Order (Dkt. 248)”). The court begins its review of this Order with the legal standard governing the objection, next. II. Legal Standard When reviewing a magistrate judge’s order deciding nondispositive pretrial matters, the district court applies a “‘clearly erroneous or contrary to law’” standard of review. First Union

Mortg. Corp. v. Smith, 229 F.3d 992, 995 (10th Cir. 2000) (quoting Ocelot Oil Corp. v. Sparrow Indus., 847 F.2d 1458, 1462 (10th Cir. 1988)); Fed. R. Civ. P. 72(a); see also 28 U.S.C. § 636(b)(1)(A). Under this clearly erroneous standard, a district judge does not review factual findings de novo; instead, it must affirm a magistrate judge’s findings unless a review of the entire evidence leaves the district judge “with the definite and firm conviction that a mistake has been committed.” Ocelot Oil Corp., 847 F.2d at 1464 (quotation cleaned up). In contrast, “the contrary to law” standard permits a district judge to conduct an independent review of purely legal determinations made by the magistrate judge. Sprint Commc’ns Co. L.P. v. Vonage Holdings Corp., 500 F. Supp. 2d 1290, 1346 (D. Kan. 2007). A magistrate judge’s order is contrary to law if it “fails to apply or misapplies relevant statutes, case law or rules of procedure.” Walker v. Bd. of Cnty. Comm’rs, No. 09-1316-MLB, 2011 WL 2790203, at *2 (D. Kan. July 14, 2011).

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Cite This Page — Counsel Stack

Bluebook (online)
Dena Burge, Leigh Hockett, Jordan Furlan, Anne Arundel County, Maryland, Cristine Ridey, and Patricia Sawczuk, individually and on behalf of all others similarly situated v. Teva Pharmaceuticals Industries, Ltd., Teva Pharmaceuticals USA, Inc., Teva Parenteral Medicines, Inc., Teva Neuroscience, Inc., Teva Sales & Marketing, Inc., Cephalon, Inc., Counsel Stack Legal Research, https://law.counselstack.com/opinion/dena-burge-leigh-hockett-jordan-furlan-anne-arundel-county-maryland-ksd-2026.